

Appl. No. 09/676,502

surprisingly were found to be useful in the treatment and cure of
Q1 asthma.

Please replace the third paragraph on page 4 with the
following rewritten paragraph:

--Further, the invention provides a method for the treatment of asthma, said method comprising the steps of administering an effective amount of the composition comprising an extract obtained from the plant *Murraya koenigii* and at least one pharmaceutically acceptable additive to a subject in need thereof.
Q2

Please replace the paragraph on page 5, lines 1-3 with the
following rewritten paragraph:

--In an embodiment, the lyophilized extract obtained from *Murraya Koenigii* is administered alone or along with other conventional additives for the treatment of asthma. In still another embodiment, the mode of administration is oral for the treatment of mild or acute asthma.
Q3

Please replace the paragraph on page 5, lines 15-18 with the
following rewritten paragraph:

--In another embodiment, the additives obtained from *M. paniculate Linn*, *H. abelmoschus*, *T. ammi*, *S. aromaticum*, *A. vasica* Nees, *E. hirta*, and *M. koinegii* are administered to include
Q4

Appl. No. 09/676,502

a4
properties such as antidiarrheal, antiseptic, carminative, stimulation, anti-cough, anti-bronchitis and nourishment.

Please replace the third paragraph on page 6 with the following rewritten paragraph:

a5
--As said above, the active factor(s) in *Murraya koenigii* useful for relief, treatment and cure of asthmatic problem(s), the preparation of which comprises drying, powdering, and extracting the dried leaves of the plant, *Murraya koenigii*, in a percolator at an ambient temperature using appropriate solvents and concentrating the extract under reduced pressure and finally lyophilizing the concentrate to make the active factor(s).

Please replace Table 1 beginning on page 10 with the following rewritten Table 1:

Appl. No. 09/676,502

--Table 1

Inhibition of arachidonic acid oxidation by neutrophil

Treatment	Micromole oxygen consumed/10 min	% of inhibition of O ₂ consumption by active material with respect to	
		Stimulation	Without stimulation
A. Phosphate Buffered Saline for 60 min.	16.08	NA	--
B. Active extract 60 min in Phosphate Buffered Saline	12.85	--	20
C. Phorbol Myristic Acetate for 30 min.	39.58	--	
D. Calcium ionophore for 30 min.	64.01	--	
E. Active extract 30min + PMA 30 min.	21.42	46	
F. Active extract 30min.+Calcium ionophore 30 min.	25.3	60	

Please replace the first paragraph on page 11 with the following rewritten paragraph:

--Calcium ionophore gave better results as there was about 60% inhibition while PMA effects 46% inhibition of O₂ consumption by active material present in *Murraya koenigii* leaf under in vitro neutrophil test. In both the stimulation remarkable inhibition of O₂ consumption indicates the efficacy of the material.--

Appl. No. 09/676,502

Please replace the fifth paragraph beginning on page 14 and ending on page 15 with the following rewritten paragraph:

--Two volunteer patients (one male and another female) with a genetic predisposition for asthma had sleepiness during night time and were very prone to asthmatic episodes due to sensitivity to the city pollution. Shortness of breathing was their main complaint, and one had to take an inhaler when a severe night attack occurred. They followed the medication as described in Case-I above for one month.

i) During nine months of observation, they did not have any asthmatic attacks,

ii) No shortness of breath was reported by them,

iii) In the case of the male patient, his smoking was a risk enhancer for an asthmatic attack. However, he did not have any breathing discomfort due to smoking even exceeding his regular schedule.

iv) The female patient had shortness of breath when she took long walks or climbed even a single staircase, but during treatment, she did not have any trouble breathing even when she climbed up to the third level.

IN THE CLAIMS:

Claims 1-12, 18, 19 and 39 have been cancelled.

The claims have been amended as follows: